Swiss Spinal Cord Injury Cohort Study (SwiSCI) Report issue

Foundation Phase 4

Organization Overview

First Clinical Trial
2019
NCT04049994
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Swiss Spinal Cord Injury Cohort Study (SwiSCI)

Active Ingredients

Drugs in Phase 4 Trials (1)

killed enterotoxigenic escherichia coli vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Infections (Phase 4)

Spinal Cord Injuries (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1